Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus SYNALAR HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN TRIAMCINOLONE ACETONIDE versus SYNALAR HP.
NYSTATIN-TRIAMCINOLONE ACETONIDE vs SYNALAR-HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
Apply topically to affected area twice daily for 2-4 weeks.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
None Documented
None Documented
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Category D/X
Category C
Corticosteroid
Corticosteroid